BLUE bluebird bio Inc.

-0.25  -0%
Previous Close 125.26
Open 123.96
Price To Book 3.89
Market Cap 6890958233
Shares 55,123,256
Volume 282,719
Short Ratio
Av. Daily Volume 481,236

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
LentiGlobin - HGB-210
Sickle Cell Disease (SCD)
Phase 3 data to be presented at EHA June 14, 2019, 11:30a.m. CEST
LentiGlobin - HGB-212 Northstar-3
TDT and the β0/β0genotype
Phase 2 data due by the end of 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 3 updated data due at EHA June 16, 2019, 8a.m. CEST
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 updated data released September 5, 2018.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data due at EHA June 14, 2019, 11:45 am. CEST
LentiGlobin - HGB-204
Phase 1/2 updated data due at EHA June 16, 2019, 8:15a.m. CEST
LentiGlobin - HGB-206
Sickle disease
Phase 1 data due by the end of 2019.
Multiple Myeloma

Latest News

  1. Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
  2. bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress
  3. Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade
  4. Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.
  5. bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies
  6. bluebird bio Flies Forward
  7. See what the IHS Markit Score report has to say about bluebird bio Inc.
  8. bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y
  9. bluebird bio Announces Investor Events in May
  10. Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
  11. Bluebird: 1Q Earnings Snapshot
  12. bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress
  13. Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine
  14. bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer
  15. 5 Biotech Stocks for a Long-Lived Portfolio
  16. Small Gains Still Bring New Highs
  17. 20 High-Growth Stocks For The Next 20 Years
  18. Is a Beat in the Cards for Molina's (MOH) Earnings in Q1?
  19. How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
  20. Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates